{"id":"comtess","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Dyskinesia"},{"rate":"10-15","effect":"Nausea"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Dizziness"},{"rate":"10-20","effect":"Urine discoloration (harmless)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Comtess (entacapone) is a peripheral COMT inhibitor that prevents the metabolism of levodopa in the periphery, allowing more levodopa to reach the brain and be converted to dopamine. By extending levodopa's half-life and duration of action, it reduces motor fluctuations and 'off' periods in Parkinson's disease patients. This is particularly useful in advanced Parkinson's disease where patients experience wearing-off effects between doses.","oneSentence":"Comtess inhibits catechol-O-methyltransferase (COMT), an enzyme that breaks down levodopa, thereby prolonging levodopa's therapeutic effect in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:30:58.951Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease (adjunctive therapy with levodopa/carbidopa to reduce motor fluctuations and 'off' periods)"}]},"trialDetails":[{"nctId":"NCT07151378","phase":"PHASE3","title":"Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2025-10-27","conditions":"PARKINSON DISEASE (Disorder)","enrollment":150},{"nctId":"NCT07313176","phase":"","title":"Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease","status":"RECRUITING","sponsor":"Britannia Pharmaceuticals Ltd.","startDate":"2026-01","conditions":"Advanced Parkinson Disease","enrollment":215},{"nctId":"NCT05043103","phase":"","title":"Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Britannia Pharmaceuticals Ltd.","startDate":"2021-07-06","conditions":"Advanced Parkinson Disease","enrollment":312},{"nctId":"NCT05579379","phase":"","title":"DESENSITIZE-PD: Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Support Dopaminergic Desensitization in PD","status":"UNKNOWN","sponsor":"University Hospital Tuebingen","startDate":"2022-10","conditions":"Parkinson Disease","enrollment":20},{"nctId":"NCT02764125","phase":"PHASE2","title":"Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2016-04-08","conditions":"Parkinson's Disease","enrollment":84},{"nctId":"NCT03103399","phase":"PHASE2","title":"Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With \"Wearingoff\" Phenomenon","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2006-09-26","conditions":"Parkinson Disease","enrollment":254},{"nctId":"NCT03094156","phase":"PHASE1","title":"Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2006-04-26","conditions":"Parkinson Disease","enrollment":39},{"nctId":"NCT03091868","phase":"PHASE1","title":"Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2004-11-03","conditions":"Parkinson Disease","enrollment":80},{"nctId":"NCT02170376","phase":"PHASE1","title":"The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2011-09","conditions":"Parkinson's Disease (PD)","enrollment":80},{"nctId":"NCT02834507","phase":"PHASE2","title":"Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2005-03","conditions":"Parkinson's Disease (PD)","enrollment":19},{"nctId":"NCT02452606","phase":"NA","title":"Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's Disease","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2015-03","conditions":"Parkinson Disease, Sleep Disorders","enrollment":100},{"nctId":"NCT01568073","phase":"PHASE3","title":"Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With \"Wearing-off\" Phenomenon","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2011-03","conditions":"Parkinson's Disease","enrollment":600},{"nctId":"NCT01766258","phase":"PHASE2","title":"Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2011-05","conditions":"Parkinson's Disease","enrollment":117},{"nctId":"NCT01296464","phase":"PHASE2","title":"Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2011-02","conditions":"Parkinson's Disease","enrollment":27},{"nctId":"NCT00491998","phase":"PHASE1, PHASE2","title":"PK, PD and Safety of Multiple Doses of V1512 Tablets in PD Patients Compared to Standard Levodopa/Carbidopa Oral Tablets","status":"COMPLETED","sponsor":"Vernalis (R&D) Ltd","startDate":"2006-11","conditions":"Parkinson's Disease","enrollment":27},{"nctId":"NCT00642356","phase":"PHASE4","title":"Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off","status":"TERMINATED","sponsor":"Novartis","startDate":"2008-03","conditions":"Parkinson's Disease","enrollment":14},{"nctId":"NCT01070628","phase":"PHASE1","title":"Levodopa Concentration Profile With Stalevo 75/125 mg","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2009-12","conditions":"Parkinson's Disease","enrollment":20},{"nctId":"NCT00247247","phase":"PHASE4","title":"Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off.","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2002-12","conditions":"Parkinson's Disease","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Comtess®","genericName":"Comtess®","companyName":"Orion Corporation, Orion Pharma","companyId":"orion-corporation-orion-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Comtess inhibits catechol-O-methyltransferase (COMT), an enzyme that breaks down levodopa, thereby prolonging levodopa's therapeutic effect in the brain. Used for Parkinson's disease (adjunctive therapy with levodopa/carbidopa to reduce motor fluctuations and 'off' periods).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}